SCHEMBL4527705

SCHEMBL4527705

O=C(O)c1ccc(-c2ccc(F)cc2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.55
TSHR P16473 1/20 0.55
CASP1 P29466 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
BCL2L1 Q07817 2/20 0.52
BAD Q92934 2/20 0.52
PDK2 Q15119 1/20 0.49
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
DHODH Q02127 1/20 0.47
AKR1C2 P52895 3/20 0.46
AKR1C1 Q04828 3/20 0.46
HNF4A P41235 1/20 0.46
ACMSD Q8TDX5 1/20 0.46
EIF4E P06730 1/20 0.45
GRIK1 P39086 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MYC P01106 1/20 0.44
NR4A1 P22736 1/20 0.44
PPP1CA P62136 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770320 0.88 TSHR (0.68) XDHTSHRCASP1SMN1; SMN2PDK2
SCHEMBL27602130 0.87 HPGD (0.46) XDHBCL2L1BADERCC5FEN1
SCHEMBL3128937 0.85 GRIK1 (0.55) XDHBCL2L1BADERCC5FEN1
SCHEMBL3417670 0.85 TSHR (0.70) XDHTSHRCASP1SMN1; SMN2PDK2
SCHEMBL120353 0.85 ACMSD (0.63) XDHTSHRCASP1SMN1; SMN2PDK2
SCHEMBL195310 0.84 TSHR (0.63) TSHRCASP1SMN1; SMN2GRIK1ALDH1A1
SCHEMBL18688873 0.83 XDH (0.60) XDHTSHRCASP1SMN1; SMN2BCL2L1
SCHEMBL30784621 0.83 XDH (0.60) XDHTSHRCASP1SMN1; SMN2BCL2L1
SCHEMBL14252284 0.82 BCL2L1 (0.57) XDHBCL2L1BADDHODHAKR1C2
SCHEMBL4652620 0.82 TTR (0.66) TSHRCASP1SMN1; SMN2PDK2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632850-B2 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS SANOFI-AVENTIS (FR) 2009-12-15 US disclosed
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy SANOFI-AVENTIS (FR) 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014830-A1 Arylalkylcarbamate derivatives production and use thereof in therapy CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 XDH 148/4885TSHR 422/4885CASP1 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.